NanoFCM's single-molecule NanoAnalyzer technology is advancing in vivo CAR-T therapy development by enabling detailed characterization of lipid nanoparticles (LNPs) used for targeted delivery. The platform measures particle sizing, counts, mRNA encapsulation efficiency, and antibody/ligand decoration without labels, facilitating quality control essential for efficient CAR-T engineering inside the body. This addresses manufacturing complexity and toxicity challenges associated with ex vivo CAR-T production. Upcoming webinars and collaborations are focusing on leveraging this technology to optimize conversion efficiency and clinical utility of in vivo CAR-T therapeutics.